# $15 billion medical AI startup OpenEvidence faces questions over accuracy

- Published: 2026-10-21T15:14:07.000Z
- Updated: 2026-10-21T22:10:46.699Z
- Section: Market
- Topics: Research
- Page: https://aidailyjournal.com/en/n/2026/10/21/15-billion-medical-ai-startup-openevidence-faces-questions-over-accuracy/
- Sources: [Ars Technica](https://arstechnica.com/ai/2026/10/the-15-billion-ad-powered-ai-startup-your-doctor-may-already-be-using)

## Summary

OpenEvidence, an ad-powered medical AI startup valued at $15 billion, is growing despite questions about the accuracy of its answers and the use of advertising. According to Ars Technica, a Mayo Clinic study found the tool’s recommendations accurate and evidence-based in five cases, but other research—including a paper published in Nature in June—found it performed worse than general-purpose models such as Google’s Gemini and OpenAI’s GPT on clinical evaluations.

The company also faces competition from OpenAI and Anthropic. Anthropic partnered with OpenEvidence to bring healthcare tools to 100 low- and middle-income countries, while Alexander Tarashansky, the creator of Claude Science, joined the startup to support its clinical work. Experts cited point to limited research on individual tools and warn that more junior doctors could rely too heavily on such systems before mastering basic knowledge.

## Why it matters (editorial interpretation)

The combination of a $15 billion valuation, advertising, and mixed study results makes clinical validation central to trust in the product. Experts’ concerns about junior doctors’ reliance on such systems also point to risks of adoption before evidence on individual tools is more established.

_Summary written by AI Daily Journal in its own words, based on the sources above. For details, read the original articles._